Alzamend NeuroALZN
13F holders, Q1 2026 (March 31)13holders
2new positions
4sold out
$1.06avg. 13F price*
At the end of Q1 2026, 13 institutions reported holding Alzamend Neuro Inc. (ALZN) in their 13F filings, unchanged from Q4 2025. 2 opened new positions and 4 sold out. The largest holders were Kingsbury Capital Investment Advisors LLC ($601K), Geode Capital Management, LLC ($48K) and Vanguard Fiduciary Trust Co. ($22K).
- Company
- Alzamend Neuro Inc.
- CUSIP
- 02262M605
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $6K |
| Exits | 4 | $257K |
All 13F filers, Q4 2025 → Q1 2026: 27,512 shares bought and 161,477 shares sold, net −133,965 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 13 holders
| Kingsbury Capital Investment Advisors LLC | 0.56% | — | 566,733 | $601K |
| Geode Capital Management, LLC | 0.00% | Add +66.1% | 45,680 | $48K |
| Vanguard Fiduciary Trust Co. | 0.00% | — | 21,020 | $22K |
| Morgan Stanley | 0.00% | No change | 18,000 | $19K |
| Clearstead Advisors, LLC | 0.00% | No change | 10,000 | $11K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +197.2% | 6,184 | $7K |
| Citigroup Inc. | 0.00% | New | 5,231 | $6K |
| UBS Group AG | 0.00% | Reduce -81.7% | 4,504 | $5K |
| Vanguard Capital Management LLC | 0.00% | — | 4,400 | $5K |
| BlackRock, Inc. | 0.00% | No change | 437 | $463 |
| SBI Securities Co., Ltd. | 0.00% | No change | 22 | $23 |
| Caitong International Asset Management Co., Ltd | 0.00% | New | 4 | $4 |
| Harbor Investment Advisory, LLC | 0.00% | No change | 1 | $1 |
"% of holder's portfolio" is ALZN's weight in each manager's 13F, not the share of Alzamend Neuro Inc. the manager owns.